BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference
BioStem Technologies (OTC: BSEM) announces its participation in the 24th Annual Needham Virtual Healthcare Conference, where CEO Jason Matuszewski will present on April 10, 2025, at 1:30 PM ET. The company will also conduct investor meetings during the conference.
BioStem Technologies specializes in developing and manufacturing placental-derived products for advanced wound care using their proprietary BioREtain® processing method. Their product portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®.
The company maintains AATB accreditation and operates an FDA-registered facility in Pompano Beach, Florida, following Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP). Their processing method focuses on maintaining growth factors and preserving tissue structure for optimal wound care solutions.
BioStem Technologies (OTC: BSEM) annuncia la sua partecipazione alla 24ª Conferenza Virtuale sulla Salute di Needham, dove il CEO Jason Matuszewski presenterà il 10 aprile 2025, alle 13:30 ET. L'azienda condurrà anche incontri con gli investitori durante la conferenza.
BioStem Technologies è specializzata nello sviluppo e nella produzione di prodotti derivati dalla placenta per la cura avanzata delle ferite, utilizzando il loro metodo di lavorazione proprietario BioREtain®. Il loro portafoglio prodotti include AmnioWrap2™, VENDAJE®, VENDAJE AC® e VENDAJE OPTIC®.
L'azienda mantiene l'accreditamento AATB e opera in una struttura registrata dalla FDA a Pompano Beach, Florida, seguendo le Buone Pratiche Tissutali (cGTP) e le Buone Pratiche di Fabbricazione (cGMP). Il loro metodo di lavorazione si concentra sul mantenimento dei fattori di crescita e sulla preservazione della struttura dei tessuti per soluzioni ottimali nella cura delle ferite.
BioStem Technologies (OTC: BSEM) anuncia su participación en la 24ª Conferencia Virtual de Salud de Needham, donde el CEO Jason Matuszewski presentará el 10 de abril de 2025, a la 1:30 PM ET. La empresa también llevará a cabo reuniones con inversores durante la conferencia.
BioStem Technologies se especializa en el desarrollo y fabricación de productos derivados de la placenta para el cuidado avanzado de heridas utilizando su método de procesamiento patentado BioREtain®. Su cartera de productos incluye AmnioWrap2™, VENDAJE®, VENDAJE AC® y VENDAJE OPTIC®.
La empresa mantiene la acreditación AATB y opera en una instalación registrada por la FDA en Pompano Beach, Florida, siguiendo las Buenas Prácticas de Tejidos (cGTP) y las Buenas Prácticas de Manufactura (cGMP). Su método de procesamiento se centra en mantener los factores de crecimiento y preservar la estructura del tejido para soluciones óptimas en el cuidado de heridas.
BioStem Technologies (OTC: BSEM)는 2025년 4월 10일 오후 1시 30분 ET에 CEO Jason Matuszewski가 발표할 24회 연례 Needham 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사는 또한 컨퍼런스 기간 동안 투자자 회의를 진행할 예정입니다.
BioStem Technologies는 독자적인 BioREtain® 가공 방법을 사용하여 고급 상처 치료를 위한 태반 유래 제품을 개발 및 제조하는 전문 회사입니다. 그들의 제품 포트폴리오에는 AmnioWrap2™, VENDAJE®, VENDAJE AC® 및 VENDAJE OPTIC®가 포함됩니다.
회사는 AATB 인증을 유지하며, 플로리다주 폼파노 비치에 있는 FDA 등록 시설에서 좋은 조직 관행(cGTP) 및 좋은 제조 관행(cGMP)을 준수하여 운영됩니다. 그들의 가공 방법은 성장 인자를 유지하고 조직 구조를 보존하여 최적의 상처 치료 솔루션을 제공하는 데 중점을 두고 있습니다.
BioStem Technologies (OTC: BSEM) annonce sa participation à la 24ème Conférence Virtuelle de Santé de Needham, où le PDG Jason Matuszewski présentera le 10 avril 2025 à 13h30 ET. L'entreprise organisera également des réunions avec des investisseurs pendant la conférence.
BioStem Technologies est spécialisée dans le développement et la fabrication de produits dérivés du placenta pour les soins avancés des plaies, en utilisant leur méthode de traitement propriétaire BioREtain®. Leur portefeuille de produits comprend AmnioWrap2™, VENDAJE®, VENDAJE AC® et VENDAJE OPTIC®.
L'entreprise maintient une accréditation AATB et opère dans une installation enregistrée par la FDA à Pompano Beach, en Floride, en suivant les Bonnes Pratiques Tissulaires (cGTP) et les Bonnes Pratiques de Fabrication (cGMP). Leur méthode de traitement se concentre sur le maintien des facteurs de croissance et la préservation de la structure des tissus pour des solutions optimales de soins des plaies.
BioStem Technologies (OTC: BSEM) gibt seine Teilnahme an der 24. jährlichen Needham Virtual Healthcare Conference bekannt, auf der CEO Jason Matuszewski am 10. April 2025 um 13:30 Uhr ET präsentieren wird. Das Unternehmen wird während der Konferenz auch Investorenmeetings durchführen.
BioStem Technologies ist auf die Entwicklung und Herstellung von plazentabasierten Produkten für die fortschrittliche Wundversorgung spezialisiert und verwendet dabei ihre proprietäre BioREtain®-Verarbeitungsmethode. Ihr Produktportfolio umfasst AmnioWrap2™, VENDAJE®, VENDAJE AC® und VENDAJE OPTIC®.
Das Unternehmen hält die AATB-Akkreditierung und betreibt eine von der FDA registrierte Einrichtung in Pompano Beach, Florida, und befolgt die Good Tissue Practices (cGTP) sowie die Good Manufacturing Practices (cGMP). Ihre Verarbeitungsmethode konzentriert sich darauf, Wachstumsfaktoren zu erhalten und die Gewebestruktur für optimale Wundversorgungslösungen zu bewahren.
- None.
- None.
The presentation will be webcast at 1:30 PM ET on April 10, 2025
POMPANO BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that its Chief Executive Officer, Jason Matuszewski, will present at the 24th Annual Needham Virtual Healthcare Conference at 1:30 PM ET on Thursday, April 10, 2025. Management will also be hosting investor meetings during the conference.
BioStem Technologies Presentation Access:
- Presenter: Jason Matuszewski, Chief Executive Officer
- Date: Thursday, April 10, 2025
- Time: 1:30 PM ET
- Webcast Link & Archive: HERE
- 1-on-1 Meeting Request: Conferences@needhamco.com
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE, and follow us on X and LinkedIn.
About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain®processing method. BioREtain®has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
For more information visit biostemtechnologies.com and follow us on X and LinkedIn.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Investor Relations
Adam Holdsworth
adamh@pcgadvisory.com
917-497-9287
FAQ
When and where will BioStem Technologies (BSEM) present at the Needham Healthcare Conference?
What products are in BioStem Technologies' (BSEM) current portfolio?
What is BioStem Technologies' (BSEM) BioREtain® processing method?
What certifications does BioStem Technologies' (BSEM) manufacturing facility have?
How can investors participate in BioStem Technologies' (BSEM) Needham Conference presentation?
